NCT00838955

Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Loyola University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial is for patients with Hodgkin Lymphoma that has not responded to standard treatment. The purpose of this study is to determine what effects, good or bad, Temsirolimus has on Hodgkin Lymphoma. The study will also determine whether Temsirolimus is tolerated in patients with Hodgkin Lymphoma who have been previously treated with chemotherapy.

Detailed description

Temsirolimus 25 mg IV infusion will be given once weekly on days 1, 8, 15 and 22 of each cycle. Patients will be assessed for response with CT scans after the second cycle, and then after every other cycle until disease progression is confirmed. Patients will be treated with Temsirolimus until disease progression, or up to six cycles. Continuation of therapy beyond cycles is at the discretion of the investigator.

Conditions

• Hodgkin's Lymphoma

Interventions

Type	Name	Description
DRUG	Temsirolimus	Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle

Timeline

• Start date: 2009-01-01
• Primary completion: 2016-10-01
• Completion: 2017-10-01
• First posted: 2009-02-09
• Last updated: 2024-07-10

Locations

1 site across 1 country: United States